ALPMF - Apellis falls as Astellas wins FDA nod for rival product
2023-08-07 13:54:42 ET
More on Apellis
- Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade)
- Apellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition Space
- Apellis extends selloff as JPMorgan becomes latest to downgrade
- Apellis off 6% as eye drug concerns weigh; BofA downgrades
- Seeking Alpha’s Quant Rating on Apellis Pharmaceuticals
For further details see:
Apellis falls as Astellas wins FDA nod for rival product